why choose us

Clinical Trials Search

Showing 15,070 of 132,656 result(s)
Mucolipidosis Type IV Natural History Study

Status: Completed

Condition: Mucolipidosis Type IV

Interventions:

Date: 2023-02-08

Efficacy of Tranexamic Acid (TXA) in Humerus ORIF

Status: Completed

Condition: Fracture Humerus

Interventions: 1 gram of TXA in 10mg single-dose ampule (100mg;mL) administered 10 minutes prior to surgery

Date: 2023-02-08

Acute Effects of Autoregulated and Non-autoregulated Blood Flow Restrictive Bicep Curls

Status: Completed

Condition: Arterial Stiffness

Interventions: Measure within & between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no B

Date: 2023-02-08

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Status: Completed

Condition: Ulcerative Colitis

Interventions: Administered IV

Date: 2023-02-08

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Status: NOT_YET_RECRUITING

Condition: Gastroesophageal Adenocarcinoma

Interventions: Blood will be collected for ctDNA testing

Date: 2023-02-08

Intraoperative Exercises & Musculoskeletal Pain in Gynecologic Surgeons

Status: Completed

Condition: Work-related Injury

Interventions: Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes.
During these breaks, surgeons will

Date: 2023-02-08

Clinical Trial for Integrated Care to Help At Risk Teen (iCHART) Intervention

Status: Completed

Condition: Suicide and Depression

Interventions:

The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (

Date: 2023-02-08

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS;MPN Neoplasms

Status: Completed

Condition: Myelodysplastic Syndromes

Interventions: Participants will be treated with Luspatercept, with a starting dose of 1.0 mg;kg subcutaneous injection every 3 weeks (administered on Day 1 of

Date: 2023-02-08

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Status: Completed

Condition: Castration-Sensitive Prostate Carcinoma

Interventions: Given PO

Date: 2023-02-08